Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update presentation at the virtual conference on Wednesday, February 12, 2025, at 2:40 p.m. ET. The event, scheduled for February 11-12, 2025, will be held entirely virtually, with a webcast link available for interested participants.

News Market Reaction – RVPH

+1.51%

+1.51% Session move

In the trading session that priced this news, RVPH gained 1.51%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference, taking place virtually February 11-12, 2025.

Oppenheimer 35^th Annual Healthcare Life Sciences Conference
Format: Corporate update
Date: Wednesday, February 12, 2025
Time: 2:40 p.m. ET
Location: Virtual
Webcast Link: Click Here

About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. 

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When is Reviva Pharmaceuticals (RVPH) presenting at the Oppenheimer Healthcare Conference 2025?

Reviva Pharmaceuticals (RVPH) will present on Wednesday, February 12, 2025, at 2:40 p.m. ET during the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference.

What therapeutic areas does RVPH focus on according to their latest conference presentation?

According to the announcement, RVPH focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.

Is the Oppenheimer Healthcare Conference 2025 where RVPH is presenting in-person or virtual?

The Oppenheimer 35th Annual Healthcare Life Sciences Conference is being held virtually from February 11-12, 2025.

Who will represent RVPH at the Oppenheimer Healthcare Conference 2025?

Laxminarayan Bhat, Ph.D., who is the Founder, President, and CEO of Reviva, will represent the company at the conference.